Palbociclib dose reductions and the effect on clinical outcomes in patients with advanced breast cancer.

ABSTRACT:

Background

This study aimed to provide insights into the real-world use of palbociclib, dose reductions, and drug effectiveness in (older) patients with advanced breast cancer (BC).

Patients and methods

Patients with advanced BC treated with palbociclib from 2017 to 2020 were included. The Kaplan-Meier method was used to calculate time to next treatment (TTNT) and overall survival (OS) for patients with or without dose reductions. These clinical outcomes were also compared in subgroup analyses for older patients (≥70 years) and younger patients (<70 years) and for patients discontinuing palbociclib early (<4 administrations).

Results

A total of 598 patients with advanced BC were included, with a median age of 64 years. Palbociclib dose reductions occurred in 33% of al

SUBMITTER: Ismail RK 

PROVIDER: S-EPMC8609048 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature